prevention

Browse trials
V2  
List  

treatment    comparator  All cause death Cardiovascular death Death from cancer Vascular death Non fatal MI Vascular events Cancer stroke (fatal and non fatal)  myocardial infarction (fatal and non fatal)  hospitalisation for heart failure cardiac death cardiovascular events Diabetes  atrial fibrillation  cardiovascular death, MI, stroke atrial fibrillation recurrence  more than one AF recurrence normoglycemia  mild-to-moderate postthrombotic syndrome mild to-severe postthrombotic syndrome  severe postthrombotic syndrome     
Voglibosediabetes type 2, in all type of patients vs placebo------------ by 54% --------
Voglibosediabetes type 2, in people with impaired glucose tolerance vs placebo------------ by 54% --------
Vogliboseimpaired fasting glucose , in all type of patients vs placebo------------ by 54% --------
Candesartanatrial fibrillation, in patient with history of atrial fibrillation vs placebo---------------------
Candesartanatrial fibrillation, in patients without history of AF (primary prevention) vs placebo-------------NS-------
Irbesartanatrial fibrillation, in patient with history of atrial fibrillation vs placebo---NS-NS-NSNS by 13% -----------
Irbesartanatrial fibrillation, in patient with history of atrial fibrillation vs control--------------- by 61% -----
Valsartanatrial fibrillation, in patient with history of atrial fibrillation vs placebo---------------NSNS----
Valsartanatrial fibrillation, in patients without history of AF (primary prevention) vs placebo------------- by 33% -------
Valsartandiabetes type 2, in all type of patients vs placeboNSNS-----NSNSNS-NS by 10% --------
Valsartandiabetes type 2, in people with impaired glucose tolerance vs placeboNSNS-----NSNSNS-NS by 10% --------
Valsartanimpaired fasting glucose , in all type of patients vs placeboNSNS-----NSNSNS-NS by 10% --------
Orlistatdiabetes type 2, in all type of patients vs placebo------------ by 57% --------
Orlistatdiabetes type 2, in people with impaired glucose tolerance vs placebo------------ by 57% --------
Glipizidediabetes type 2, in all type of patients vs placebo------------NS--------
Glipizidediabetes type 2, in people with impaired glucose tolerance vs placebo------------NS--------
Metformindiabetes type 2, in all type of patients vs control------------NS--------
Metformindiabetes type 2, in all type of patients vs placebo------------ by 33% ----NS---
Metformindiabetes type 2, in people with impaired glucose tolerance vs control------------NS--------
Metformindiabetes type 2, in people with impaired glucose tolerance vs placebo------------ by 50% ----NS---
Metforminimpaired fasting glucose , in all type of patients vs placebo------------ by 50% ----NS---
Nateglinidediabetes type 2, in all type of patients vs placeboNSNS-----NSNSNS-NSNS--------
Nateglinidediabetes type 2, in people with impaired glucose tolerance vs placeboNSNS-----NSNSNS-NSNS--------
Nateglinideimpaired fasting glucose , in all type of patients vs placeboNSNS-----NSNSNS-NSNS--------
Rosiglitazonediabetes type 2, in all type of patients vs placeboNSNS--------- by 52% by 53% -NS-- by 110% ---
Rosiglitazonediabetes type 2, in people with impaired glucose tolerance vs placeboNSNS--------- by 52% by 53% -NS-- by 110% ---
Rosiglitazoneimpaired fasting glucose , in all type of patients vs placeboNSNS--------- by 52% by 53% -NS-- by 110% ---
Troglitazonediabetes type 2, in all type of patients vs placebo---------------------
Troglitazonediabetes type 2, in people with impaired glucose tolerance vs placebo---------------------
Enalaprilatrial fibrillation, in patient with history of atrial fibrillation vs control---------------NS-----
Enalaprilatrial fibrillation, in patients without history of AF (primary prevention) vs placebo------------- by 78% -------
Lisinoprilatrial fibrillation, in patients without history of AF (primary prevention) vs placebo-------------NS-------
Lisinoprilatrial fibrillation, in patient with history of atrial fibrillation vs placebo---------------NS-----
Ramiprildiabetes type 2, in all type of patients vs placeboNSNS---------NSNS----NS---
Ramiprildiabetes type 2, in people with impaired glucose tolerance vs placeboNSNS---------NSNS----NS---
Ramiprilimpaired fasting glucose , in all type of patients vs placeboNSNS---------NSNS----NS---
Gemfibrozilatrial fibrillation, in patients without history of AF (primary prevention) vs placebo-------------NS-------
Losartanatrial fibrillation, in patients without history of AF (primary prevention) vs atenolol------------- by 34% -------
Glarginediabetes type 2, in all type of patients vs placebo---------------------
Glarginediabetes type 2, in people with impaired glucose tolerance vs placebo---------------------
Glargineimpaired fasting glucose , in all type of patients vs placebo---------------------
Dietdiabetes type 2, in all type of patients vs AHA 1 diet------------NS--------
Dietdiabetes type 2, in people with impaired glucose tolerance vs AHA 1 diet------------NS--------
Folic acidpost stroke, in patients with prior stroke or TIA vs placebo-----------NS---------
Folic acidpost stroke, in patients with prior stroke or TIA vs low dose - folic acid, vit B12 and vit B6NS---NS--NS---NS---------
Atorvastatinatrial fibrillation, in patient with history of atrial fibrillation vs control---------------NS-----
Atorvastatinatrial fibrillation, in patient with history of atrial fibrillation vs placebo--------------- by 36% -----
Atorvastatinatrial fibrillation, in patients without history of AF (primary prevention) vs placebo-------------NS-------
Pravastatinatrial fibrillation, in patient with history of atrial fibrillation vs control---------------NS-----
Rosuvastatinatrial fibrillation, in patients without history of AF (primary prevention) vs placebo---------------------